Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19
Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19
Abstract
Objective: This study analyzed the phenotypic and antifungal resistance profile of fungi isolated from pulmonary infections in critically patients with COVID-19. Materials and methods: Information was obtained on fungal strains isolated at the National Reference Laboratory of Mycology (LRNM) from hospitalized patients with COVID-19. The Fungi were identified by mass spectrometry (MALDI-TOF) and molecular techniques, classifying phenotypes and evaluating antifungal sensitivity according to the Clinical & Laboratory Standards Institute (CLSI). Antifungals such as anidulafungin, micafungin, caspofungin, voriconazole, fluconazole, itraconazole and amphotericin B were tested. Results: In yeasts, Candida albicans was the predominant species (73,5%), followed by Candida tropicalis (19,3%). In filamentous fungi, Aspergillus fumigatus was the most frequent (78,3%), followed by Aspergillus terreus (17,4%). Most strains of Candida albicans were sensitive to antifungals, with a small percentage resistant to fluconazole. In Aspergillus fumigatus, voriconazole was effective in 77.8% of cases, with some strains categorized as intermediate or resistant. In general, Candida and Aspergillus strains showed sensitivity to echinocandins and azoles, with minimal resistance. The variability in the minimum inhibitory concentrations of the different species was reflected in the data obtained. Conclusions: Candida albicans and Aspergillus fumigatus were the predominant fungi, with general sensitivity to echinocandins and azoles, although some resistant strains were observed, especially to fluconazole and voriconazole. These findings highlight the importance of accurate diagnosis and appropriate therapeutic management in fungal infections, underlining the need to customize treatments according to the species and its sensitivity profile.
Downloads
Published
2025-03-06
How to Cite
Paredes-Gago, R., Valencia-Vásquez, P. G., Úrcia-Ausejo, F. C., Escalante-Maldonado, O. R., & Ayala-Mendívil, R. E. (2025). Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19. Peruvian Journal of Health Care and Global Health, 9(1). Retrieved from http://revista.uch.edu.pe/index.php/hgh/article/view/305
Issue
Section
Original articles
License
Copyright (c) 2025 Rolando Paredes-Gago, Pedro Gustavo Valencia-Vásquez, Flor Cecilia Úrcia-Ausejo, Oscar Roberto Escalante-Maldonado, Ronald Espíritu Ayala-Mendívil
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The authors will retain their copyright and will guarantee to the journal right of first publication of their work, which will simultaneously be under a Creative Commons Attribution 4.0 License that allows third parties to share the work whenever attribuying their author and first publication in this journal.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post online a pre-publication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
